We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Purpose
This guidance is for Australian sponsors and manufacturers of medicines, active pharmaceutical ingredients (APIs) and sunscreens made or supplied in Australia.
It provides a summary of the changes in good manufacturing practice (GMP) requirements resulting from the recent replacement of the PIC/S Guide to GMP for Medicinal Products (PE 009-16, 1 February 2022) with PE 009-17, 25 August 2023.
The most significant change resulting from the adoption of the more recent version of the PIC/S Guide related to updates to Annex 1 for the manufacture of sterile medicinal products.
There are no other changes to the guidance, therefore manufactures of non-sterile medicines, non-sterile active pharmaceutical ingredients (APIs) and sunscreens are not materially affected by this update.
Changes to the PIC/S Guide to GMP
From 1 September 2025 the PIC/S Guide to GMP version 17 applies to the manufacture of medicines, APIs and sunscreens, unless exempt under provisions in the Therapeutic Goods Act 1989 (the Act).
There is a 6-month transition period for adoption of some changes to Annex 1 to allow manufacturers to review and make necessary operational changes. The guidance below provides details of these changes and expected actions and timeframes for compliance.